Insight

Feb 7, 2025, 13:25

Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer

Giampaolo Bianchini, Head of the Translational and Immunotherapy Research Group at the San Raffaele Scientific Institute – Milan, shared on X:

“IMpassion030 just out in JAMA! A negative trial, but a crucial lesson:

In TNBC (as in many solid tumors), peri-operative chemo-immunotherapy is more effective than adjuvant chemo-immunotherapy.”

Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial | Breast Cancer | JAMA | JAMA Network

Authors: Michail Ignatiadis, Andrew Bailey, Heather McArthur, Sarra El-abed, Evandro de Azambuja, Otto Metzger, Stephen Y. Chui, Max Dieterich, Thomas Perretti, Esther Shearer-Kang, Luciana Molinero, Günther G. Steger, Jacek Jassem, Soo Chin Lee, Michaela Higgins, Jose Zarba, Marcus Schmidt, Henry Gomez, Angel Guerrero Zotano, Luca Moscetti, Joanne Chiu, Elisabetta Munzone, Noa Efrat Ben-Baruch, Emilio Bajetta, Shinji Ohno, Seock-Ah Im, Gustavo Werutsky, Einav Nili Gal-Yam, Xavier Gonzalez Farre, Ling-Ming Tseng, William Jacot, Oleg Gluz, Zhimin Shao, Yaroslav Shparyk, Anastasia Zimina, Eric Winer, David A. Cameron, Giuseppe Viale, Shigehira Saji, Richard Gelber, Martine Piccart

Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer

Anastasia Zimina Andrew Bailey Angel Guerrero-Zotano cancer David A Cameron Einav Nili Gal-Yam Elisabetta Munzone Emilio Bajetta Eric Winer Esther Shearer-Kang Evandro de Azambuja Giampaolo Bianchini Giuseppe Viale Günther G. Steger Gustavo Werutsky Heather McArthur Henry Gomez Jacek Jassem Joanne Chiu Jose Zarba Ling-Ming Tseng Luca Moscetti Luciana Molinero Marcus Schmidt Martine Piccart Max Dieterich Michaela Higgins Michail ignatiadis Noa Efrat Ben-Baruch Oleg Gluz OncoDaily Oncology Otto Metzger Richard Gelber Sarra El-abed Seock-Ah Im Shigehira Saji Shinji Ohno Soo Chin Lee Stephen Y. Chui Thomas Perretti William Jacot Xavier Gonzalez-Farré Yaroslav Shparyk Zhimin Shao

Oncologist Near Me – Fedro Alessandro Peccatori: Leading Expert in Gynecological Oncology

MATTERHORN trial - FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer

Daiichi Sankyo's and Astrazeneca's press release on ENHERTU®: Latest Updates from DESTINY-Gastric04 trial

13-year-old Cancer Survivor Sworn in as a Secret Service agent by President Trump - The White House

The European Parliament Intergroup on Cancer and Rare Diseases has been set in motion - ECO